Login / Signup

A STAT5B-CD9 axis determines self-renewal in hematopoietic and leukemic stem cells.

Sebastian KollmannReinhard GrausenburgerThorsten KlampflMichaela Prchal-MurphyKlavdija BastlHanja PisaVanessa M KnabTania BrandstoetterEszter DomaWolfgang R SperrSabine LaggerMatthias FarlikRichard H MorigglPeter ValentFlorian HalbritterKaroline KollmannGerwin HellerBarbara MaurerVeronika Sexl
Published in: Blood (2022)
The transcription factors signal transducer and activator of transcription 5A (STAT5A) and STAT5B are critical in hematopoiesis and leukemia. They are widely believed to have redundant functions, but we describe a unique role for STAT5B in driving the self-renewal of hematopoietic and leukemic stem cells (HSCs/LSCs). We find STAT5B to be specifically activated in HSCs and LSCs, where it induces many genes associated with quiescence and self-renewal, including the surface marker CD9. Levels of CD9 represent a prognostic marker for patients with STAT5-driven leukemia, and our findings suggest that anti-CD9 antibodies may be useful in their treatment to target and eliminate LSCs. We show that it is vital to consider STAT5A and STAT5B as distinct entities in normal and malignant hematopoiesis.
Keyphrases
  • stem cells
  • cell proliferation
  • acute myeloid leukemia
  • bone marrow
  • transcription factor
  • immune response
  • smoking cessation
  • dna binding
  • replacement therapy